This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: Q28.3 (Other malformations of cerebral vessels) | Special Copayment Reduction: V191 (Special copayment reduction for cerebrovascular disease: 5% copayment for up to 30 days from the registration date) |
| B. Synonyms | Congenital cerebrovascular malformation (excluding arteriovenous malformation), cavernous malformation, developmental venous anomaly, capillary telangiectasia, congenital cerebral aneurysm |
| C. Adult onset | The age of onset differs by type: cavernous malformation presents with hemorrhage or seizures in the 20s-40s, and capillary telangiectasia is mostly asymptomatic. |
| 1. History | Beginning with pathological descriptions in the 19th century, the introduction of MRI made antemortem diagnosis and classification of cavernous malformations and others possible. |
| 2. Causes | Abnormal embryonic vascular development; caused by structural malformation at the level of capillaries, veins, and sinusoids. |
| 3. Genetics | Familial cavernous malformation: CCM1 (KRIT1), CCM2 (MGC4607), CCM3 (PDCD10) mutations; sporadic cases are explained by a somatic double-mutation mechanism. |
| 4. General epidemiology | Prevalence of cavernous malformation: about 50-100 per 100,000 population; DVA (developmental venous anomaly): 2-3% of imaging findings; capillary telangiectasia: about 0.1-0.7% of autopsies. |
| 5. Pathophysiology | It differs by malformation type; vessel wall structural defects, hemodynamic abnormalities, and endothelial dysfunction are common mechanisms. |
| 6. Symptoms | Cavernous malformation: headache, seizures, focal neurological deficits, hemorrhage; DVA: mostly asymptomatic; capillary telangiectasia: almost always asymptomatic; congenital cerebral aneurysm: many asymptomatic before rupture. |
| 7. Signs | Signs of focal neurological deficits due to hemorrhage or nerve compression; brainstem cavernous malformations may present with cranial nerve palsies, among others. |
| 8. Screening | Brain MRI (including SWI sequences) is the most effective screening; regular MRI follow-up recommended in familial CCM. |
| 9. Diagnosis | MRI (T2*, SWI, FLAIR, contrast T1) is central; DSA is needed to differentiate AVM; genetic testing is performed in familial CCM. |
| 10. Treatment | Symptomatic cavernous malformation: surgical resection or SRS; DVA and capillary telangiectasia: observation; congenital aneurysm: coil embolization or clip ligation after rupture risk assessment. |
| 11. Prognosis | Varies by lesion type and location; seizure control rate after resection of cavernous malformation 70-80%; DVA and capillary telangiectasia have a very good prognosis. |
| 12. Prevention | Primary prevention is impossible because it is congenital; in familial CCM, genetic counseling, regular MRI, and optimization of antiseizure medication constitute secondary prevention. |
| 13. References | Akers A et al. Synopsis of guidelines for the clinical management of cerebral cavernous malformations … and 9 other papers |
Other malformations of cerebral vessels (Q28.3) is a code collectively referring to various congenital structural abnormalities of cerebral vessels not included in arteriovenous malformations (AVM, Q28.0·Q28.2), representatively including cavernous malformation (CM; cavernoma), developmental venous anomaly (DVA), capillary telangiectasia, and congenital cerebral aneurysm.
Cavernous malformations began to be known when 19th-century pathologists described at autopsy brain lesions filled with "cave-like (cavernous)" vascular spaces. However, even in the CT era (1970s), small cavernous malformations often went undetected. In 1988, Zabramski described in the Journal of Neurosurgery the imaging features of cavernous malformations on MRI—the "popcorn appearance"—opening the era of antemortem diagnosis.
DVA (developmental venous anomaly) began to be recognized with advances in angiography and MRI in the 1970s-1980s and was formerly called venous angioma. When Lasjaunias et al. systematized the pathophysiology and clinical characteristics of DVA in 1986, it was established that most DVAs follow a benign course.
The genetic causes of familial cerebral cavernous malformation (FCCM) were identified from the 1990s onward when linkage analysis confirmed three gene loci: CCM1 (7q21), CCM2 (7p15), and CCM3 (3q25). Subsequently, KRIT1, MGC4607, and PDCD10 were identified as the respective genes. Capillary telangiectasia is difficult to detect even on CT/MRI and is mainly diagnosed through autopsy reports or special MRI sequences (SWI); most are incidental findings with almost no clinical significance. Congenital intracranial aneurysms constitute a portion of all cerebral aneurysms and are understood to involve vessel wall fragility due to collagen and elastic layer defects formed from the embryonic period.
The pathogenesis of Q28.3 malformations differs by type of malformation, but they are commonly caused by abnormalities in embryonic vascular development.
The pathogenesis of cavernous malformation (CM) is that dysfunction of proteins regulating junctions between vascular endothelial cells—KRIT1, Malcavernin, PDCD10—causes abnormal dilation of the vessel wall at the capillary level, forming sinusoidal vascular spaces. These vessel walls lack a capsule and are in direct contact with surrounding brain tissue, and hemosiderin is deposited due to repeated microhemorrhages.
Developmental venous anomaly (DVA) is a malformation in which the normal venous drainage pathway fails to develop during venous development, so normal venous tributaries abnormally converge into a single large collector vein. DVA itself often contributes to venous drainage of normal brain tissue, so its removal can cause venous infarction.
Capillary telangiectasia is a malformation in which dilated capillaries are scattered among normal neural tissue, caused by structural abnormalities of vascular endothelial cells. Most are located in the pons and are clinically almost harmless. Congenital cerebral aneurysm is explained by defects of the intima and media of the vessel wall—connective tissue weakening, absence of the internal elastic lamina—present from the embryonic period at branch points of the circle of Willis, causing the vessel wall to bulge under blood pressure.
Among the malformations included in Q28.3, the one whose genetic mechanism is best understood is cavernous malformation (CM).
Familial cerebral cavernous malformation (FCCM) follows an autosomal dominant inheritance pattern and is caused by mutations in three genes. The CCM1 (KRIT1) gene (7q21) encodes the KRIT1 protein, which is central to maintaining junctions between endothelial cells (adherens junction, tight junction). The CCM2 (MGC4607/Malcavernin) gene (7p15) binds KRIT1 and regulates the permeability of vascular endothelial cells. The CCM3 (PDCD10) gene (3q25) regulates cell survival and migration and is associated with the most severe phenotype (multiple CMs in infancy).
Knudson's two-hit hypothesis applies to FCCM: CM forms when a second mutation occurs in somatic cells in addition to one germline mutation. This model explains why CMs appear as multiple lesions in FCCM. Somatic double mutations are also being identified in sporadic CM.
DVA and capillary telangiectasia are mostly sporadic, with no clear genetic cause. However, DVA and CM are often found together in FCCM patients, and the formation of CM around a DVA is understood as the DVA providing a local hemodynamic environment that promotes CM formation. Congenital cerebral aneurysms have been reported to be associated with connective tissue diseases (EDS, Marfan, Loeys-Dietz syndrome) and polycystic kidney disease (ADPKD, PKD1/PKD2), and familial aggregation studies suggest some genetic predisposition.
The epidemiology of the various malformations included in Q28.3 differs greatly by malformation type.
Cavernous malformation (CM) is the second most common type among all cerebral vascular malformations. In population-based studies, the prevalence is estimated at about 50-100 per 100,000 population (about 0.05-0.1%). MRI studies have also reported a prevalence of about 0.5%. The male-to-female ratio is nearly equal, and FCCM is found at high frequency in the Mexican Hispanic population due to a specific CCM1 founder mutation.
Developmental venous anomaly (DVA) is the most common cerebral vascular malformation, found in about 2-3% of the adult population in MRI studies. Most are solitary and most commonly located in the cerebellum and frontal lobe. Most are asymptomatic and clinically insignificant, but symptoms sometimes arise from an associated CM.
For capillary telangiectasia, autopsy studies report a prevalence of about 0.1-0.7%; it is the smallest and clinically harmless vascular malformation. It is mainly located in the pons. Congenital cerebral aneurysms constitute a portion of all cerebral aneurysms (about 1-5% of the population), and those found in childhood and adolescence are regarded as congenital. Branch points of the circle of Willis—the anterior communicating artery, the middle cerebral artery bifurcation, and the origin of the posterior communicating artery—are the most common sites.
The mechanisms of Q28.3 malformations vary by type, but functional and structural abnormalities at the level of vascular endothelial cells are the common core.
In cavernous malformation, loss of function of the KRIT1, Malcavernin, and PDCD10 proteins destabilizes the junctional complex between endothelial cells, increasing vascular permeability and causing sinusoidal dilation. Repeated microhemorrhages form a hemosiderin rim around the lesion, and this hemosiderin irritates the surrounding brain tissue and causes epilepsy. Oxidative damage from iron ions within the lesion contributes to further vessel wall damage and lesion growth.
The mechanism of DVA is explained as the formation of a "compensatory venous pathway," in which the normal venous drainage pathway fails to form during embryonic development and primitive medullary veins overdevelop and converge into a single collector vein. The abnormal hemodynamic environment around a DVA (low flow velocity, high viscosity) can cause local vascular damage and promote CM formation.
Capillary telangiectasia takes the form of dilated capillaries scattered among normal neural tissue, and unlike normal capillaries the vessel walls are thin and composed only of endothelial cells. This increases vascular permeability, but because they are not exposed to arterial pressure, the risk of hemorrhage is very low. The development of congenital cerebral aneurysm is a phenomenon in which hemodynamic stress concentrates at vessel branch points and the intima bulges outward at sites where smooth muscle of the tunica media is lacking; hypertension and turbulent flow worsen this.
The clinical symptoms of the various Q28.3 malformations differ greatly by type.
In cavernous malformation (CM), various symptoms appear due to repeated microhemorrhages. Headache is the most common symptom, and in acute hemorrhage, sudden headache, nausea, and focal neurological deficits occur. Epileptic seizures are common in CMs located in the cerebral cortex (about 50-70% of symptomatic CMs experience seizures), and when seizures are difficult to control, quality of life is greatly reduced. CMs located in the brainstem may show a course in which focal cranial nerve palsies (facial palsy, abducens palsy, dysphagia), limb weakness, and ataxia worsen in a stepwise manner with each hemorrhage.
DVA is mostly asymptomatic. When symptoms are present, they are usually due to an associated CM, and symptoms caused by pure DVA itself are very rare. Rarely, focal neurological deficits may occur when thrombus (venous thrombosis) forms. Capillary telangiectasia is almost always asymptomatic and discovered incidentally. Congenital cerebral aneurysm is mostly asymptomatic when unruptured, but upon rupture, subarachnoid hemorrhage occurs with sudden excruciating headache (thunderclap headache), which is a medical emergency. Large unruptured aneurysms can cause symptoms by compressing nearby cranial nerves—oculomotor (third) nerve palsy (ptosis, mydriasis, exotropia).
Physical examination findings of Q28.3 malformations vary depending on the type and location of the malformation and the presence of hemorrhage.
When hemorrhage occurs in cavernous malformation, characteristic neurological signs appear depending on the lesion location. With cerebral hemispheric hemorrhage, hemiparesis, hemisensory loss, aphasia, and hemianopia may appear. With cerebellar CM hemorrhage, ataxia, nystagmus, and gait disturbance may appear, and with brainstem (especially pontine) CM hemorrhage, diplopia, facial palsy (cranial nerve VII), facial sensory loss (cranial nerve V), limb motor weakness, and Horner syndrome may appear.
Todd paralysis (transient hemiparesis) may be observed after an epileptic seizure. In FCCM patients, accompanying cutaneous vascular malformations (multiple cutaneous hemangiomas) can be a diagnostic clue. In DVA and capillary telangiectasia, physical examination is generally normal. In congenital cerebral aneurysm, signs of nerve compression by a large aneurysm before rupture—oculomotor (third) nerve palsy (complete or incomplete ptosis, pupillary dilation, ocular abduction)—are a signal for emergency neurological evaluation. After rupture, signs of meningeal irritation (neck stiffness, Kernig sign) and altered consciousness appear.
Brain MRI (especially including SWI/T2* sequences) is the most sensitive and effective test for screening Q28.3 malformations.
Cavernous malformation characteristically appears on SWI (susceptibility weighted imaging) or T2*-weighted images as a mixed-signal lesion with a "popcorn appearance" and a surrounding dark hemosiderin rim. On FLAIR (fluid-attenuated inversion recovery) images, edema around the lesion may be observed, and on contrast-enhanced T1 images some CMs show mild enhancement. SWI detects CMs about 5 times more sensitively than T2*.
In patients suspected of familial CCM—those with a confirmed CCM gene mutation or an FCCM patient among first-degree relatives—initial screening with brain MRI (including SWI) followed by periodic (every 1-5 years) follow-up MRI is recommended. DVA and capillary telangiectasia can be screened on contrast-enhanced T1 images ("caput medusae of vessels" and "faint punctate enhancement"), but most are incidental findings. When acute hemorrhage or an epileptic seizure is present, non-contrast CT followed by MRI is performed to evaluate for CM.
Brain MRI is the diagnostic standard for most Q28.3 malformations, including cavernous malformation. A protocol including multi-echo sequences—T1, T2, FLAIR, T2*, SWI, contrast-enhanced T1—comprehensively evaluates the lesion's morphology, size, location, stage of hemorrhage, and relationship to surrounding brain tissue.
MRI findings of cavernous malformation: on T2/SWI, a mixed-signal core (a mixture of hemosiderin, oxyhemoglobin, and deoxyhemoglobin) and a surrounding low-signal hemosiderin rim form the characteristic "popcorn appearance." Contrast enhancement is often mild or absent. On DSA, CMs usually appear normal because the vessels do not fill (cryptic vascular malformation), and DSA is performed to exclude AVM.
DVA is diagnosed on contrast-enhanced MRI by a "Caput Medusae" appearance in which multiple venous tributaries converge into a collector vein. On DSA, characteristic radial venous convergence is confirmed in the venous phase. Congenital cerebral aneurysms are screened with CTA or MRA and finally confirmed with DSA, and the treatment plan is established by evaluating size, shape (saccular vs. fusiform), neck width, and relationship to adjacent vessels. Genetic testing targeting the CCM1, CCM2, and CCM3 genes is performed when FCCM is suspected.
Treatment of Q28.3 malformations varies greatly depending on malformation type, presence of symptoms, lesion location, and bleeding risk.
In cavernous malformation, the key to treatment decisions is balancing surgical risk against the risk of the natural history without treatment. For symptomatic cerebral CMs (recurrent hemorrhage or uncontrolled seizures), surgical resection is preferred when located in an accessible site. With complete resection, the seizure-freedom rate is about 60-80%, and hemorrhage recurrence is almost absent. Because brainstem CMs carry high surgical risk, surgery is considered only for recurrent hemorrhage or neurological deterioration. The effect of stereotactic radiosurgery (SRS) in CM is less clear than in AVM, but it is selectively used for inoperable brainstem CMs. Antiseizure medications (AED) are used for seizure control, and continuation for 2-5 years even after surgery is often recommended.
DVA is in principle not a target for treatment. Because DVA is responsible for venous drainage of normal brain tissue, its removal can cause venous infarction, so it must be preserved. When an associated CM causes symptoms, only the CM is selectively resected while the DVA is preserved. Capillary telangiectasia has no clinical significance, requires no treatment, and is only observed. For congenital cerebral aneurysm, endovascular coiling, surgical clipping, or observation (small, asymptomatic, low-risk aneurysms) is chosen according to size, shape, location, and the patient's age and general condition.
The prognosis of Q28.3 malformations differs greatly by malformation type.
In the natural history of cavernous malformation, the hemorrhage risk is about 2-3% per year and higher in brainstem CMs (about 5%). After an initial hemorrhage, the risk of rebleeding rises to 20-30% within the first 2 years. After complete surgical resection, the risk of rebleeding almost disappears, and the seizure control rate is about 60-80%. In brainstem CMs, repeated hemorrhage leads to stepwise neurological deterioration, and the long-term prognosis may be poor.
The prognosis of DVA is very good. Neurological damage caused by pure DVA itself is rare, and most DVAs remain asymptomatic for life. When symptoms due to an associated CM are a problem, the prognosis after CM treatment depends on the characteristics and location of the CM. The prognosis of capillary telangiectasia is benign, with almost no effect on clinical outcomes. The prognosis of congenital cerebral aneurysm depends greatly on whether it ruptures; upon rupture, mortality is about 40% and neurological disability about 30-50%, which is serious. After successful treatment (coiling or clipping), the rerupture rate is very low. Because new lesions can develop throughout life in FCCM patients, regular follow-up is important.
Because Q28.3 malformations are congenital, primary prevention is impossible. The focus is on secondary prevention and minimizing complications.
Management of families of FCCM patients is an important preventive intervention. Genetic counseling and genetic testing are offered to first-degree relatives of patients with a confirmed CCM gene mutation, and brain MRI (including SWI) screening is performed in mutation carriers. This allows early detection of asymptomatic CMs and establishment of a management plan before neurological abnormalities develop.
Secondary prevention in patients with cavernous malformation: In patients with seizures, antiseizure medications are started early to prevent seizure-related injury. Control of known risk factors for CM hemorrhage—normalizing blood pressure, cautious use of anticoagulants and antiplatelet agents—is important. CM patients need caution with contact sports or activities with a high risk of head trauma. For DVA and capillary telangiectasia, regular outpatient follow-up without specific preventive measures is sufficient. When there is a family history of congenital cerebral aneurysm, screening with brain MRA or CTA in first-degree relatives is considered, and blood pressure control and smoking cessation help suppress aneurysm growth.
Akers A, Al-Shahi Salman R, A Awad I, et al. Synopsis of guidelines for the clinical management of cerebral cavernous malformations: consensus recommendations based on systematic literature review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. Neurosurgery. 2017;80(5):665-680. DOI: 10.1093/neuros/nyx091. PMID: 28387844.
Rigamonti D, Hadley MN, Drayer BP, et al. Cerebral cavernous malformations. Incidence and familial occurrence. N Engl J Med. 1988;319(6):343-347. DOI: 10.1056/NEJM198808113190605. PMID: 3393196.
Lasjaunias P, Burrows P, Planet C. Developmental venous anomalies (DVA): the so-called venous angioma. Neurosurg Rev. 1986;9(3):233-242. DOI: 10.1007/BF01743835. PMID: 3540980.
Riant F, Bergametti F, Ayrignac X, et al. Recent insights into cerebral cavernous malformations: the molecular genetics of CCM. FEBS J. 2010;277(5):1070-1075. DOI: 10.1111/j.1742-4658.2009.07536.x. PMID: 20085591.
Abdulrauf SI, Kaynar MY, Awad IA. A comparison of the clinical profile of cavernous malformations with and without associated venous malformations. Neurosurgery. 1999;44(1):41-47. DOI: 10.1097/00006123-199901000-00024. PMID: 9894961.
Gross BA, Lin N, Du R, Day AL. The natural history of intracranial cavernous malformations. Neurosurg Focus. 2011;30(6):E24. DOI: 10.3171/2011.2.FOCUS1157. PMID: 21631215.
Zabramski JM, Wascher TM, Spetzler RF, et al. The natural history of familial cavernous malformations: results of an ongoing study. J Neurosurg. 1994;80(3):422-432. DOI: 10.3171/jns.1994.80.3.0422. PMID: 8113851.
Rivero-Arias O, Campbell H, Gray A, et al. Surgical treatment compared with conservative management for intracranial cavernous malformations: a systematic review. J Neurosurg. 2010;112(5):1047-1059. DOI: 10.3171/2009.8.JNS09817. PMID: 19817536.
Kim BS, Sarkar S, Abdulrauf SI. Management of cavernous malformations of the brainstem. Neurosurg Clin N Am. 2012;23(1):103-116. DOI: 10.1016/j.nec.2011.09.019. PMID: 22107857.
Kim SH, Shin HC, Kim MH. Cerebral cavernous malformations: analysis of prognostic factors following surgery. J Korean Neurosurg Soc. 2013;54(3):199-204. DOI: 10.3340/jkns.2013.54.3.199. PMID: 24278641.